Abstract
The Effect of Bevacizumab-Related Hypertension on the Prognosis of Patients with Colorectal Cancer and Non-Small Cell Lung Cancer
Department of Pathology, 1Department of Hematology, Taizhou First People’s Hospital, Taizhou, Zhejiang 318020, China
Correspondence Address:
Weizhi Zheng, Department of Pathology, Taizhou First People’s Hospital, Taizhou, Zhejiang 318020, China, E-mail: 13586201201@163.com
To study and analyze the effect of bevacizumab-related hypertension on the prognosis of patients with colorectal cancer and non-small cell lung cancer. The study randomly selected 100 colorectal cancer patients and 100 non-small cell lung cancer patients who received therapy in our hospital from October 2019 to October 2021. Among them, adopted intervention for 100 colorectal cancer patients with bevacizumab combined with cytotoxic drug chemotherapy and adopted intervention for 100 non-small cell lung cancer patients with bevacizumab combined with standard chemotherapy. Bevacizumab treatment has better therapeutic effect of hypertension on colorectal cancer patients than non-small cell lung cancer patients. Compared with colorectal cancer patients who received bevacizumab treatment, non-small cell lung cancer patients under bevacizumab treatment caused more adverse reactions. Among 100 colorectal cancer patients, the number of patients with bevacizumab-related hypertension in grade 1, grade 2 and grade 3 were 45, 12 and 23 respectively. Among 100 non-small cell lung cancer patients, the number of patients with bevacizumab-related hypertension in grade 1, grade 2 and grade 3 were 44, 25 and 20 respectively. Bevacizumab-related hypertension can improve the prognosis and efficacy of colorectal cancer and nonsmall cell lung cancer patients.
